Cargando…

Decade in review: a new era for RET-rearranged lung cancers

Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhury, Noura J., Drilon, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815364/
https://www.ncbi.nlm.nih.gov/pubmed/33489819
http://dx.doi.org/10.21037/tlcr-20-346
_version_ 1783638214284673024
author Choudhury, Noura J.
Drilon, Alexander
author_facet Choudhury, Noura J.
Drilon, Alexander
author_sort Choudhury, Noura J.
collection PubMed
description Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first identified more than thirty years ago, targeted therapy for RET fusion-positive lung cancers was only explored in the last decade. Whereas repurposed multikinase inhibitors were initially tested, selective inhibitors RET inhibitors have dramatically improved outcomes for patients whose tumors harbor these alterations. In 2020, the US Food and Drug Administration approved selpercatinib, a selective RET inhibitor, for adults with lung and thyroid cancers with RET rearrangements or mutations, making it the first targeted therapy to be approved for RET-altered cancers. While resistance to selective RET inhibition has been described, next-generation RET inhibitors are already being explored for patients who progress on prior RET kinase inhibitors.
format Online
Article
Text
id pubmed-7815364
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-78153642021-01-22 Decade in review: a new era for RET-rearranged lung cancers Choudhury, Noura J. Drilon, Alexander Transl Lung Cancer Res Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first identified more than thirty years ago, targeted therapy for RET fusion-positive lung cancers was only explored in the last decade. Whereas repurposed multikinase inhibitors were initially tested, selective inhibitors RET inhibitors have dramatically improved outcomes for patients whose tumors harbor these alterations. In 2020, the US Food and Drug Administration approved selpercatinib, a selective RET inhibitor, for adults with lung and thyroid cancers with RET rearrangements or mutations, making it the first targeted therapy to be approved for RET-altered cancers. While resistance to selective RET inhibition has been described, next-generation RET inhibitors are already being explored for patients who progress on prior RET kinase inhibitors. AME Publishing Company 2020-12 /pmc/articles/PMC7815364/ /pubmed/33489819 http://dx.doi.org/10.21037/tlcr-20-346 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
Choudhury, Noura J.
Drilon, Alexander
Decade in review: a new era for RET-rearranged lung cancers
title Decade in review: a new era for RET-rearranged lung cancers
title_full Decade in review: a new era for RET-rearranged lung cancers
title_fullStr Decade in review: a new era for RET-rearranged lung cancers
title_full_unstemmed Decade in review: a new era for RET-rearranged lung cancers
title_short Decade in review: a new era for RET-rearranged lung cancers
title_sort decade in review: a new era for ret-rearranged lung cancers
topic Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815364/
https://www.ncbi.nlm.nih.gov/pubmed/33489819
http://dx.doi.org/10.21037/tlcr-20-346
work_keys_str_mv AT choudhurynouraj decadeinreviewaneweraforretrearrangedlungcancers
AT drilonalexander decadeinreviewaneweraforretrearrangedlungcancers